GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » Float Percentage Of Total Shares Outstanding

Medicenna Therapeutics (TSX:MDNA) Float Percentage Of Total Shares Outstanding : 27.74% (As of May. 23, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Medicenna Therapeutics's float shares is 20.74 Mil. Medicenna Therapeutics's total shares outstanding is 74.78 Mil. Medicenna Therapeutics's float percentage of total shares outstanding is 27.74%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Medicenna Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Medicenna Therapeutics's Institutional Ownership is 0.05%.

Medicenna Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Medicenna Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=20.74/74.78
=27.74%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicenna Therapeutics (TSX:MDNA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
TSX:RVX TSXV:SBM XCNQ:DOSE TSXV:NRX NEOE:BMND TSXV:IBT XCNQ:MDMA XCNQ:COOL XCNQ:TELI TSXV:COV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MDNAF:USA
Address
2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2
Website
https://www.medicenna.com
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
Executives
Albert George Beraldo Director
Chandra Panchal Director

Medicenna Therapeutics (TSX:MDNA) Headlines

No Headlines